Omisirge Market 2026–2035 strengthening stem cell transplantation

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Omisirge Market Over The Period 2026–2030?

The expansion observed in the historic period can be ascribed to a surge in hematologic cancer cases, the inherent drawbacks of traditional cord blood transplantation, the preliminary clinical achievements of cell expansion technologies, the widening application of allogeneic stem cell transplants, and the numerous regulatory clearances for advanced cell-based treatments.

The anticipated market expansion during the forecast period is propelled by factors such as the broadening of personalized cell therapy pipelines, a surge in investments within regenerative medicine, the wider integration of advanced transplantation procedures, an amplified commitment to mitigating post-transplant complications, and the enlargement of infrastructure for cell therapy production.

Key developments projected for the forecast period include a growing acceptance of expanded cord blood therapies, increased application of ex vivo cell expansion methodologies, an intensified drive for quicker neutrophil engraftment, the proliferation of allogeneic hematopoietic stem cell transplantation (HSCT) uses, and advancements in manufacturing scalability for cell therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20269&type=smp

What Underlying Factors Are Accelerating The Growth Of The Omisirge Market?

The increasing necessity for personalized treatments is anticipated to foster the expansion of the omisirge market. Personalized treatments involve medical interventions specifically adapted to an individual’s unique genetic makeup, environmental influences, and lifestyle choices to maximize effectiveness and minimize adverse reactions. The uptick in demand for these tailored therapies stems from advances in genetic research, heightened awareness of individualized healthcare, and the growing recognition that customized treatments offer superior efficacy and fewer side effects compared to conventional, generalized approaches. Omisirge plays a role in enhancing personalized treatments by its capacity to adjust to individual patient needs, target specific immune responses, and optimize therapeutic outcomes based on the distinct characteristics of each patient’s cancer profile. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, noted that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, marking a notable increase from the six approved in 2022. Thus, the escalating demand for personalized treatments is projected to propel the growth of the omisirge market.

How Is The Omisirge Market Divided Into Its Major Segments?

The omisirge market covered in this report is segmented –

1) By Clinical Indication: Leukemia, Lymphoma, Myeloma, Other Hematologic Malignancies

2) By Distribution Channel: Direct Sales, Distributors

3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers

How Are Trends Transforming The Omisirge Market Landscape?

Key players within the Omisirge market are focusing on developing technological advancements, such as omidubicel-onlv, to enhance transplant efficiency and improve patient recovery outcomes. Omidubicel-onlv represents an allogeneic, stem-cell-based therapy derived from umbilical cord blood, engineered to enhance cell expansion for faster engraftment. For instance, in May 2023, the U.S. Food and Drug Administration, a US-based federal agency, approved Gamida Cell’s product Omisirge, which aims to improve stem cell engraftment and reduce infection risks in transplant patients. This FDA approval of Omisirge introduced an enhanced, expanded cord-blood-derived cell therapy designed to accelerate neutrophil recovery and lower infection risk in patients with hematologic malignancies. It offers a more reliable engraftment profile compared to traditional cord blood, making transplants faster and clinically safer.

Who Are The Prominent Organizations Shaping The Omisirge Market?

Major companies operating in the omisirge market are Gamida Cell Ltd.

Read the full omisirge market report here:

https://www.thebusinessresearchcompany.com/report/omisirge-global-market-report

Which Region Is Projected To Dominate The Omisirge Market During The Forecast Period?

North America was the largest region in the omisirge market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omisirge market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Omisirge Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20269&type=smp

Browse Through More Reports Similar to the Global Omisirge Market 2026, By The Business Research Company

Premium Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/premium-finance-global-market-report

Future Of Cv Depot Charging Market Report 2026

https://www.thebusinessresearchcompany.com/report/future-of-cv-depot-charging-global-market-report

Spend Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/spend-analytics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795